A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump
A Study Investigating the Pharmacokinetic and Pharmacodynamic Properties and Safety and Tolerability of NNC0471-0119 H When Administered as Bolus in a Continuous Subcutaneous Insulin Infusion Regimen in Participants With Type 1 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
-
Neuss, Germany, 41460
- Profil Institut für Stoffwechselforschung GmbH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged 18-64 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with Type 1 Diabetes (T1D) greater than or equal to (≥) 1 year before screening.
- Insulin administration using continuous subcutaneous insulin infusion via a pump greater than or equal to (≥) 90 days before screening.
- Current daily insulin treatment between 0.2 and 1.2 Insulin units per kilogram per day [(I)U/kg/day] (both inclusive).
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NNC0471-0119 H then Insulin Aspart
Participants will receive NNC0471-0119 H subcutaneously (s.c.) in period 1 followed by insulin aspart s.c. in period 2.
|
NNC0471-0119 H will be administered subcutaneously.
Insulin aspart will be administered subcutaneously.
|
|
Active Comparator: Insulin Aspart then NNC0471-0119 H
Participants will receive insulin aspart s.c. in period 1 followed by s.c.
NNC0471-0119 H in period 2.
|
NNC0471-0119 H will be administered subcutaneously.
Insulin aspart will be administered subcutaneously.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUC(GIR,0-1h,basal-corrected): Area under the basal-corrected glucose infusion rate (GIR)-time curve from 0 to 1 hour
Time Frame: 0 to 1 hour after bolus infusion
|
Measured in milligram per kilogram (mg/kg).
|
0 to 1 hour after bolus infusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUC(GIR,0-t,basal-corrected): Area under the basal-corrected GIR-time curve from 0 to t
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in milligram per kilogram (mg/kg).
|
0 to 9 hours after bolus infusion
|
|
AUC(GIR,0-1h,basal-corrected)/AUC(GIR,0-t,basalcorrected):Ratio of the area under the basal-corrected GIR-time curve from 0 to 1 hour and 0 to t
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in percentage (%).
|
0 to 9 hours after bolus infusion
|
|
GIR(max,basal-corrected): Maximum observed basal-corrected GIR
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in milligrams per kilogram *minute (mg/[kg*min]).
|
0 to 9 hours after bolus infusion
|
|
AUC(NNC0471-0119,0-30min,basal corrected)/AUC(NNC0471-0119,0-t,basal-corrected):Ratio of basal-corrected area under serum NNC0471-0119 conc. time curve from 0-30min and 0-t
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in percentage (%).
|
0 to 9 hours after bolus infusion
|
|
AUC(NNC0471-0119,0-t,basal-corrected): Area under the basal-corrected serum NNC0471-0119 concentration time curve from 0 to t
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in hours*picomole per liter (h*pmol/L).
|
0 to 9 hours after bolus infusion
|
|
AUC(NNC0471-0119,0-30min,basal-corrected): Area under the basal-corrected serum NNC0471-0119 concentration time curve from 0 to 30 minutes
Time Frame: 0 to 30 minutes after bolus infusion
|
Measured in h*pmol/L.
|
0 to 30 minutes after bolus infusion
|
|
AUC(NNC0471-0119,2h-t,basal-corrected): Area under the basal-corrected serum NNC0471-0119 concentration time curve from 2 hours to t, where t is the first time the curve is back to basal level after bolus infusion (at most 9 hours)
Time Frame: 2 to 9 hours after bolus infusion
|
Measured in h*pmol/L.
|
2 to 9 hours after bolus infusion
|
|
AUC(NNC0471-0119,2h-t,basal-corrected)/AUC(NNC0471-0119 H,0-t,basal-corrected):Ratio of basal corrected area under serum NNC0471-0119 conc. time curve from 2hrs-t and 0-t
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in percentage (%).
|
0 to 9 hours after bolus infusion
|
|
C(max,NNC0471-0119,basal-corrected): Maximum observed basal-corrected serum NNC0471-0119 concentration
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in picomoles per litre (pmol/L).
|
0 to 9 hours after bolus infusion
|
|
t(early50%Cmax,NNC0471-0119,basal-corrected): Time to early 50% maximum observed basal-corrected serum NNC0471-0119 concentration
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in minutes (Min).
|
0 to 9 hours after bolus infusion
|
|
t(late50%Cmax,NNC0471-0119,basal-corrected): Time to late 50% maximum observed basal-corrected serum NNC0471-0119 concentration
Time Frame: 0 to 9 hours after bolus infusion
|
Measured in minutes (Min).
|
0 to 9 hours after bolus infusion
|
|
Number of adverse events (AEs)
Time Frame: From start of first investigational medicinal product (IMP) basal rate infusion (Visit 2, day -1) until completion of post-treatment end of study visit (Visit 4)
|
Measure in number of events.
|
From start of first investigational medicinal product (IMP) basal rate infusion (Visit 2, day -1) until completion of post-treatment end of study visit (Visit 4)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Metabolic Diseases
- Autoimmune Diseases
- Immune System Diseases
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Nutritional and Metabolic Diseases
- Diabetes Mellitus, Type 1
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Peptide Hormones
- Peptides
- Amino Acids, Peptides, and Proteins
- Insulins
- Pancreatic Hormones
- Insulin, Short-Acting
- Insulin Aspart
Other Study ID Numbers
Other Study ID Numbers
- NN1471-7712
- U1111-1306-8005 (Other Identifier: World Health Organization (WHO))
- 2024-513472-18 (Other Identifier: European Medical Agency (EMA))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.